MK-8228 vs. Placebo in Prevention of CMV infection in HSCT Recipients

• Research type

  Research Study

• Full title

  A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

• IRAS ID

  144196

• Contact name

  Karl Peggs

• Contact email

  k.peggs@ucl.ac.uk

• Sponsor organisation

  Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

• Eudract number

  2013-003831-31

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  14/LO/0604

• Date of REC Opinion

  3 Jun 2014

• REC opinion

  Further Information Favourable Opinion